Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03378414
Other study ID # SCLnow-XY-03
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date December 31, 2024
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Sclnow Biotechnology Co., Ltd.
Contact Lei Guo
Phone 861064368977
Email georgeguo@sclnow.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.


Description:

This is a random, open label, and parallel controled experiment. 45 patients are selected and sign consent forms, then divided into three groups. Doctors collect the basic information of patient (including age,height, mental condition, vital sign, history of disease, pharmaco-history, genotype test, and so on.) All patients receive laboratory and image examination as baseline. Then, they will give cell treatment based on the clinical protocol. Doctors have follow-up visit on 1, 2, 3, 6, and 12 months after treatment, and do efficacy evaluation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 45
Est. completion date December 31, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 16 Years to 60 Years
Eligibility Inclusion Criteria: - Clinical and genomic test diagnoses as spinocerebellar ataxias (SCA) (include SCA 1, SCA 2, SCA 3, SCA 6), SARA (Scale for Assessment and Rating of Ataxia) score is 2-5, can complete 8-meter walking test(8MW) - Do not receive stem cells treatment in 6 months - Participants sign the consent form based on the experiment process and statement Exclusion Criteria: - Cardiac, renal, hepatic insufficiency; total bilirubin is 1.5 times higher than normal value, aspartate transaminase(AST)or alanine aminotransferase(ALT)is 2.5 times higher than normal value - Hemogram: total white blood cells <3.0 * 10^9 cells/L, blood platelet <75 * 10^9/L, hemoglobin <100g/L - pneumonia, or severe infection - With severe allergic history - Brain organic disorder, like brain tumor - Serum with HIV, syphilis antibody positive - Severe mental disease, cognitive disorder patients - Other severe system or organ organic disease - Pregnant, breast feeding, or planning pregnant women - Participate other clinical experiments in 3 months - With some other conditions that doctor propose not to participate

Study Design


Intervention

Procedure:
Intravenous infusion
Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml)
Intrathecal injection
Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml)
Biological:
umbilical cord mesenchymal stem cell
Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sclnow Biotechnology Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Scale for the assessment anf rating of ataxia (SARA) Based on SARA score to calculate treatment efficacy. The equation is as follow, Efficacy = (patients who accepted treatment are effective/patients who accepted treatment)* 100% Effective: after 12 months, score of patient decrease 1 point or more; Ineffective: after 12 months, score decrease less than 1 point or increase. 12 months
Secondary Image examinations MRI plain scan of brain. 12 months
Secondary Inventory of Non-Ataxia Symptoms (INAS) score Using Inventory of Non-Ataxia Symptoms (INAS) score to determine the presence and severity of non-ataxia signs. 12 months
Secondary Cerebrospinal fluid (csf) routine Patients is observed by professionals, compare the changes of each observation point and baseline. Baseline is the data acquire from patients before stem cells treatment. 12 months
See also
  Status Clinical Trial Phase
Completed NCT00992771 - Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Phase 2
Completed NCT01096082 - Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Phase 2/Phase 3
Active, not recruiting NCT03701399 - Troriluzole in Adult Subjects With Spinocerebellar Ataxia Phase 3
Active, not recruiting NCT04229823 - Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
Active, not recruiting NCT04419974 - Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
Terminated NCT05490563 - STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia Phase 2/Phase 3
Withdrawn NCT04301284 - Study of CAD-1883 for Spinocerebellar Ataxia Phase 2
Withdrawn NCT01096095 - Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3 Phase 2
Active, not recruiting NCT04268147 - Instrumented Data Exchange for Ataxia Study
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Active, not recruiting NCT05826171 - Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia N/A
Recruiting NCT04399265 - Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3 N/A
Completed NCT03885167 - Identification of Biomarkers in Spinocerebellar Ataxia 3
Terminated NCT05160558 - A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 Phase 1
Recruiting NCT05822908 - A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD Phase 1/Phase 2
Completed NCT05502432 - Repetitive Transcranial Magnetic Stimulation in SCA3 Patients N/A
Recruiting NCT04714307 - Neuropsychiatry and Cognition in SCA3/MJD
Recruiting NCT05557786 - Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
Recruiting NCT01060371 - Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias